169 related articles for article (PubMed ID: 8021739)
1. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.
Schwartzentruber DJ; Hom SS; Dadmarz R; White DE; Yannelli JR; Steinberg SM; Rosenberg SA; Topalian SL
J Clin Oncol; 1994 Jul; 12(7):1475-83. PubMed ID: 8021739
[TBL] [Abstract][Full Text] [Related]
2. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
3. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
[TBL] [Abstract][Full Text] [Related]
4. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response.
Pockaj BA; Sherry RM; Wei JP; Yannelli JR; Carter CS; Leitman SF; Carasquillo JA; Steinberg SM; Rosenberg SA; Yang JC
Cancer; 1994 Mar; 73(6):1731-7. PubMed ID: 8156501
[TBL] [Abstract][Full Text] [Related]
5. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.
Rosenberg SA; Yannelli JR; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
J Natl Cancer Inst; 1994 Aug; 86(15):1159-66. PubMed ID: 8028037
[TBL] [Abstract][Full Text] [Related]
6. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.
Besser MJ; Shapira-Frommer R; Itzhaki O; Treves AJ; Zippel DB; Levy D; Kubi A; Shoshani N; Zikich D; Ohayon Y; Ohayon D; Shalmon B; Markel G; Yerushalmi R; Apter S; Ben-Nun A; Ben-Ami E; Shimoni A; Nagler A; Schachter J
Clin Cancer Res; 2013 Sep; 19(17):4792-800. PubMed ID: 23690483
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
Nguyen LT; Saibil SD; Sotov V; Le MX; Khoja L; Ghazarian D; Bonilla L; Majeed H; Hogg D; Joshua AM; Crump M; Franke N; Spreafico A; Hansen A; Al-Habeeb A; Leong W; Easson A; Reedijk M; Goldstein DP; McCready D; Yasufuku K; Waddell T; Cypel M; Pierre A; Zhang B; Boross-Harmer S; Cipollone J; Nelles M; Scheid E; Fyrsta M; Lo CS; Nie J; Yam JY; Yen PH; Gray D; Motta V; Elford AR; DeLuca S; Wang L; Effendi S; Ellenchery R; Hirano N; Ohashi PS; Butler MO
Cancer Immunol Immunother; 2019 May; 68(5):773-785. PubMed ID: 30747243
[TBL] [Abstract][Full Text] [Related]
8. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698
[TBL] [Abstract][Full Text] [Related]
9. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.
Radvanyi LG; Bernatchez C; Zhang M; Fox PS; Miller P; Chacon J; Wu R; Lizee G; Mahoney S; Alvarado G; Glass M; Johnson VE; McMannis JD; Shpall E; Prieto V; Papadopoulos N; Kim K; Homsi J; Bedikian A; Hwu WJ; Patel S; Ross MI; Lee JE; Gershenwald JE; Lucci A; Royal R; Cormier JN; Davies MA; Mansaray R; Fulbright OJ; Toth C; Ramachandran R; Wardell S; Gonzalez A; Hwu P
Clin Cancer Res; 2012 Dec; 18(24):6758-70. PubMed ID: 23032743
[TBL] [Abstract][Full Text] [Related]
10. Tumor localization by tumor infiltrating lymphocytes labeled with indium-111 in patients with metastatic renal cell carcinoma, melanoma, and colorectal cancer.
Dillman RO; Hurwitz SR; Schiltz PM; Barth NM; Beutel LD; Nayak SK; O'Connor AA
Cancer Biother Radiopharm; 1997 Apr; 12(2):65-71. PubMed ID: 10851449
[TBL] [Abstract][Full Text] [Related]
11. Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens.
Hom SS; Schwartzentruber DJ; Rosenberg SA; Topalian SL
J Immunother Emphasis Tumor Immunol; 1993 Jan; 13(1):18-30. PubMed ID: 8435428
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
Itoh K; Tilden AB; Balch CM
Cancer Res; 1986 Jun; 46(6):3011-7. PubMed ID: 3486040
[TBL] [Abstract][Full Text] [Related]
13. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
[TBL] [Abstract][Full Text] [Related]
14. Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation.
Schwartzentruber DJ; Topalian SL; Mancini M; Rosenberg SA
J Immunol; 1991 May; 146(10):3674-81. PubMed ID: 1902860
[TBL] [Abstract][Full Text] [Related]
15. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
[TBL] [Abstract][Full Text] [Related]
16. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2.
Arienti F; Belli F; Rivoltini L; Gambacorti-Passerini C; Furlan L; Mascheroni L; Prada A; Rizzi M; Marchesi E; Vaglini M
Cancer Immunol Immunother; 1993 May; 36(5):315-22. PubMed ID: 8477417
[TBL] [Abstract][Full Text] [Related]
18. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy.
Marincola FM; Venzon D; White D; Rubin JT; Lotze MT; Simonis TB; Balkissoon J; Rosenberg SA; Parkinson DR
Cancer Res; 1992 Dec; 52(23):6561-6. PubMed ID: 1423301
[TBL] [Abstract][Full Text] [Related]
19. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma.
Fisher B; Packard BS; Read EJ; Carrasquillo JA; Carter CS; Topalian SL; Yang JC; Yolles P; Larson SM; Rosenberg SA
J Clin Oncol; 1989 Feb; 7(2):250-61. PubMed ID: 2644399
[TBL] [Abstract][Full Text] [Related]
20. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
